IR
IRON.US Disc Medicine Inc.
- Market cap
- USD 3.64B
- P/E
- -
- P/B
- 6.03x
- ROE
- -40.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IRON.US undervalued?
Graham numberThe Graham number of Disc Medicine Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Disc Medicine Inc. fundamental analysis
No fundamental analysis for Disc Medicine Inc. yet.
Disc Medicine Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynth…
Full company profileDisc Medicine Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Disc Medicine Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -322K | -192K | -300K | -100K | -156K | -281K | - |
| Operating Income | -34.0M | -30.9M | -47.5M | -91.1M | -130M | -236M | -265M |
| EBITDA | -33.7M | -33.8M | -47.4M | -76.2M | -108M | -208M | -238M |
| Net Income | -40.8M | -36.0M | -46.1M | -76.4M | -109M | -212M | -243M |
| EPS | -27 | -45 | -44 | -3.42 | -3.96 | -6.01 | -6.26 |
| Balance Sheet | |||||||
| Total Assets | 8.32M | 92.4M | 200M | 368M | 497M | 807M | 699M |
| Total Liabilities | 30.2M | 157M | 23.6M | 22.9M | 53.2M | 67.1M | 95.2M |
| Shareholders' Equity | -21.9M | -64.2M | 177M | 345M | 444M | 740M | 604M |
| Cash & Short-term Investments | 4.50M | 88.0M | 195M | 360M | 490M | 791M | 683M |
| Total Debt | 21.6M | 7.06M | 1.33M | 2.10M | 30.0M | 1.86M | 61.1M |
| Cash Flow | |||||||
| Operating Cash Flow | -32.7M | -27.5M | -42.3M | -73.5M | -93.9M | -180M | -196M |
| Capital Expenditure | 22.0K | 68.0K | 151K | 89.0K | 505K | 933K | 0.00 |
| Free Cash Flow | -32.7M | -27.6M | -42.4M | -73.6M | -94.4M | -181M | -196M |
| Ratios | |||||||
| ROE | - | - | -26.1% | -22.1% | -24.7% | -28.7% | -40.3% |
| ROA | -490.9% | -38.9% | -23.0% | -20.8% | -22.0% | -26.3% | -34.8% |
| Debt to Equity | - | - | 0.01x | 0.01x | 0.07x | 0.00x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Disc Medicine Inc. dividends
Disc Medicine Inc. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:30 on Dec 30, 2022.
Who owns Disc Medicine Inc.
- Insiders 6.56%
- Institutions 93.44%
- Public & others 0.00%
- Shares outstanding 45.5M
- Free float 40.1M
Top funds holding IRON.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Strategic Advisers Fidelity US TtlStk | 2.26M | 4.96% | +4.97% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 979K | 2.15% | +0.46% | Sep 2026 |
| iShares Russell 2000 ETF | 829K | 1.82% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 772K | 1.70% | +2.69% | Oct 2026 |
| JPMorgan Mid Cap Growth I | 651K | 1.43% | -1.56% | Sep 2026 |
| T. Rowe Price New Horizons | 459K | 1.01% | -11.03% | Sep 2026 |
| Fidelity Select Biotechnology | 455K | 1.00% | 0.00% | Aug 2026 |
| Eventide Healthcare & Life Sciences I | 395K | 0.87% | 0.00% | Jun 2026 |
| Fidelity Select Health Care | 380K | 0.83% | -5.00% | Aug 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 376K | 0.82% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 310K | 0.68% | +0.14% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 309K | 0.68% | -0.38% | Oct 2026 |
| Fidelity Small Cap Growth | 278K | 0.61% | 0.00% | Aug 2026 |
| JPMorgan Small Cap Growth A | 259K | 0.57% | -19.00% | Sep 2026 |
| Pictet-Biotech P USD | 251K | 0.55% | +0.38% | Jul 2026 |
| Loomis Sayles Small Cap Growth Instl | 248K | 0.54% | 0.00% | Sep 2026 |
| abrdn Healthcare Investors | 243K | 0.53% | +48.75% | Oct 2026 |
| MEDICAL BioHealth EUR Acc | 242K | 0.53% | +0.02% | Aug 2026 |
| Fidelity Stock Selector Small Cap | 235K | 0.52% | +6.04% | Aug 2026 |
| iShares Biotechnology ETF | 221K | 0.49% | -0.19% | Oct 2026 |
Top institutions holding IRON.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 4.89M | 10.75% | -12.39% | Jun 2026 |
| BlackRock Inc | 2.47M | 5.42% | +8.53% | Jun 2026 |
| RA Capital Management, LLC | 2.45M | 5.38% | 0.00% | Jun 2026 |
| JPMorgan Chase & Co | 1.88M | 4.12% | +36.77% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 1.88M | 4.12% | +21.04% | Jun 2026 |
| Wellington Management Company LLP | 1.74M | 3.82% | +0.34% | Jun 2026 |
| State Street Corp | 1.65M | 3.62% | -2.91% | Jun 2026 |
| Vestal Point Capital LP | 1.55M | 3.40% | +121.43% | Jun 2026 |
| Atlas Venture Life Science Advisors, LLC | 1.51M | 3.32% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.37M | 3.01% | -0.47% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 1.35M | 2.98% | 0.00% | Jun 2026 |
| TCG Crossover Management, LLC | 1.34M | 2.95% | 0.00% | Jun 2026 |
| Bvf Inc | 1.15M | 2.53% | -9.33% | Jun 2026 |
| Woodline Partners LP | 958K | 2.10% | 0.00% | Jun 2026 |
| Siren, L.L.C. | 888K | 1.95% | -10.12% | Jun 2026 |
| Logos Global Management LP | 875K | 1.92% | +56.25% | Jun 2026 |
| Opaleye Management Inc | 855K | 1.88% | +103.09% | Jun 2026 |
| Geode Capital Management, LLC | 790K | 1.73% | +6.11% | Jun 2026 |
| Assenagon Asset Management SA | 768K | 1.69% | +40.65% | Jun 2026 |
| Deerfield Management Co | 657K | 1.44% | 0.00% | Jun 2026 |
Disc Medicine Inc. company profile
- Company name
- Disc Medicine Inc.
- Ticker
- IRON.US
- Exchange
- USA Stocks
- Listed since
- Aug 12, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 173
- Fiscal year end
- December
- Address
- 321 Arsenal Street, Watertown, MA, United States, 02472
- Phone
- 617 674 9274
- Website
- discmedicine.com
About Disc Medicine Inc.
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts.
Disc Medicine Inc. management
10- Dr. Donald William Nicholson Ph.D.Executive Chairman · born 1957
- Dr. John D. Quisel Esq., J.D., Ph.D.CEO, President & Director · born 1971
- Ms. Jean M. Franchi CPAChief Financial Officer · born 1966
- Mr. Jonathan Yu M.B.A.Chief Opearating Officer · born 1981
- Dr. William Jacob Savage M.D., Ph.D.Chief Medical Officer · born 1974
- Ms. Pamela Stephenson M.P.H.Chief Commercial Officer · born 1968
- Dr. Brian MacDonald ChB, MB, Ph.D.Founder & Chair of Scientific Advisory Board · born 1961
- Dr. Rahul Rajan Kaushik Ph.D.Chief Technical Officer
- Dr. Rahul Khara J.D., Pharm.D.Chief Legal Officer & Secretary · born 1982
- Ms. Lisa Amaya PriceChief Human Resources Officer